Time point | Measurement | Mode | V0 | V1 | V2 | V3 |
---|---|---|---|---|---|---|
Enrollment | ||||||
Eligibility screening | Telephone | x | ||||
Screening assessment | MMSE [85] | On-site paper | x | x | x | |
Logical Memory [53] | On-site paper | x | x | x | ||
TMT A [54] | On-site paper | x | x | x | ||
On-site paper | x | x | x | |||
IADL [55] | On-site paper | x | x | x | ||
Signed informed consent | On-site | x | ||||
Allocation/randomization | x | |||||
Intervention |
| |||||
Assessments | ||||||
Baseline variables | ||||||
Demographic information | Age, civil status, education | On-site paper | x | |||
Family history | Dementia, Parkinson disease, and stroke | On-site paper | x | |||
Subjective cognitive function | ECog-39 [87] | On-site paper | x | |||
Lifestyle (lifelong) | LEQ [88] | At-home paper | x | |||
CAI [89] | On-site interview | x | ||||
Personality | BFI-10 [90] | On-site paper | x | |||
SVF-78 [91] | On-site paper | x | ||||
Hand preference | Oldfield Hand Preference [92] | On-site paper | x | |||
Premorbid IQ | MWT [93] | On-site paper | x | |||
Genetic markers | APOE ε4 status | On-site | x | |||
Cerebral PET (optional consent) | Aβ status | On-site | x | |||
Primary outcome | ||||||
Memory | MST [38] | On-site Computer | x | x | x | |
Secondary outcomes | ||||||
Memory | VLMT [94] | On-site paper | x | x | x | |
Doors and People [95] | On-site paper | x | x | x | ||
Executive function | Digit Symbol [96] | On-site paper | x | x | x | |
TMT B [54] | On-site paper | x | x | x | ||
Block Tapping [97] | On-site paper | x | x | x | ||
Stroop [98] | On-site paper | x | x | x | ||
Attention | Digit Span [96] | On-site paper | x | x | x | |
TAP [99] subtests: alertness and divided attention | On-site Computer | x | x | |||
Language | Semantic/Phonemic Fluency [100] | On-site | x | x | x | |
Boston Naming Test [100] | On-site paper | x | x | x | ||
Lifestyle (current) | ||||||
Physical activity | FKA [101] | At-home paper | x | x | x | |
Cognitive activity | CAI Present [89] | On-site interview | x | x | x | |
Sleep quality | PSQI [102] | At-home paper | x | x | x | |
Diet | At-home paper | x | x | x | ||
On-site paper | x | x | x | |||
At-home paper | x | x | x | |||
Psycho-affective/worry | At-home paper | x | x | x | ||
RSQ-D [107] | On-site paper | x | x | x | ||
STAI-G [108] | On-site paper | x | x | x | ||
Quality of life | SF-12 [109] | On-site paper | x | x | x | |
WHOQOL-BREF [110] | At-home paper | x | x | x | ||
Autophagy markers from muscle biopsy (optional consent) | LC3 I/II, p62 [72], EP300 [111], proteomics, metabolomics [73] | On-site | x | x | ||
Blood-based markers | Polyamine levels [33], metabolomics, proinflammatory biomarkers, and neurotrophin levels | On-site | x | x | ||
Cerebral neuroimaging markers | Brain structure, perfusion, function | On-site | x | x | ||
Exploratory outcomes | ||||||
Subjective cognitive function | ECog-39, adapted [87] | On-site paper | x | x | x | |
MMQ, adapted [112] | On-site paper | x | x | x | ||
Cardiovascular risk factors | Blood pressure, lipid profile, glucose metabolism | On-site | x | x | x | |
Muscle function/strength* | SPPB [113] | On-site | x | x | x | |
Handgrip strength | On-site | x | x | x |